MA50532A - Compositions et méthodes pour le traitement de cancers - Google Patents
Compositions et méthodes pour le traitement de cancersInfo
- Publication number
- MA50532A MA50532A MA050532A MA50532A MA50532A MA 50532 A MA50532 A MA 50532A MA 050532 A MA050532 A MA 050532A MA 50532 A MA50532 A MA 50532A MA 50532 A MA50532 A MA 50532A
- Authority
- MA
- Morocco
- Prior art keywords
- cancers
- compositions
- treatment
- methods
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581179P | 2017-11-03 | 2017-11-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50532A true MA50532A (fr) | 2020-09-09 |
Family
ID=66332377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050532A MA50532A (fr) | 2017-11-03 | 2018-11-05 | Compositions et méthodes pour le traitement de cancers |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12343428B2 (fr) |
| EP (1) | EP3703653A4 (fr) |
| MA (1) | MA50532A (fr) |
| WO (1) | WO2019090255A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020154716A1 (fr) * | 2019-01-26 | 2020-07-30 | University Of Rochester | Compositions et méthodes de traitement du cancer de la prostate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| WO2004078677A2 (fr) | 2003-03-07 | 2004-09-16 | Celator Pharmaceuticals, Inc. | Transfert ameliore de sphingolipides |
| EP1610763A2 (fr) | 2003-03-31 | 2006-01-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ensembles de lipides contenant des amphiphiles de formation non liposomique |
| KR20060015534A (ko) | 2003-04-25 | 2006-02-17 | 더 펜 스테이트 리서치 파운데이션 | 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템 |
| US20050267060A1 (en) | 2004-03-19 | 2005-12-01 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
| US10045953B2 (en) | 2006-07-06 | 2018-08-14 | Case Western Reserve University | Ceramide composition and method of use |
| US8747869B2 (en) | 2010-03-19 | 2014-06-10 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| WO2012088414A1 (fr) | 2010-12-23 | 2012-06-28 | Ludwig Institute For Cancer Research Ltd. | Formulation liposomale de céramides non-glycosidiques et leurs utilisations |
| EP2717856B1 (fr) * | 2011-05-10 | 2016-11-23 | The Penn State Research Foundation | Compositions de liposomes anioniques à teneur en céramide |
| US8828391B2 (en) * | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| EP2968143B1 (fr) * | 2013-03-15 | 2019-04-24 | Memorial Sloan Kettering Cancer Center | Inversion resistance a plusieurs medicaments par ceramide |
| US20150157646A1 (en) * | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| US20170306042A1 (en) * | 2014-08-29 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis |
| CN104922067A (zh) * | 2014-12-08 | 2015-09-23 | 上海张江生物技术有限公司 | 一种载药纳米脂质体、制备方法及用途 |
| EP3352753A4 (fr) * | 2015-09-24 | 2019-03-13 | The Regents of The University of California | Molécules de type sphingolipide synthétiques, médicaments, procédés pour leur synthèse et procédés de traitement |
-
2018
- 2018-11-05 MA MA050532A patent/MA50532A/fr unknown
- 2018-11-05 EP EP18871955.3A patent/EP3703653A4/fr active Pending
- 2018-11-05 WO PCT/US2018/059259 patent/WO2019090255A1/fr not_active Ceased
- 2018-11-05 US US16/761,114 patent/US12343428B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3703653A1 (fr) | 2020-09-09 |
| EP3703653A4 (fr) | 2021-09-08 |
| US20200268665A1 (en) | 2020-08-27 |
| WO2019090255A1 (fr) | 2019-05-09 |
| US12343428B2 (en) | 2025-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
| EP3687981A4 (fr) | Compositions et méthodes de traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| EP3302379A4 (fr) | Compositions et méthodes pour le traitement du ptérygion | |
| EP3347469A4 (fr) | Méthodes et compositions pour le traitement du glaucome | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| EP3462883A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| EP3801578A4 (fr) | Méthodes et compositions pour le traitement de c. difficile | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| EP3347025A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| MA45675A (fr) | Méthodes et compositions permettant le traitement du cancer | |
| EP3405191A4 (fr) | Méthodes et compositions pour le traitement de l'hyperhidrose | |
| EP3688023A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3638293A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3353204A4 (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3458079A4 (fr) | Compositions et méthodes pour le traitement de l'acné | |
| EP3386522A4 (fr) | Compositions et méthodes pour le traitement du cancer du sein métastatique her2-positif | |
| EP3651801A4 (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| EP3365014A4 (fr) | Méthodes et compositions pour le traitement de la mastocytose systémique | |
| EP3478284A4 (fr) | Composés et compositions pour le traitement du cancer | |
| EP3522865A4 (fr) | Méthodes et compositions pour le traitement de vergetures | |
| MA55093A (fr) | Méthodes et compositions pour le traitement du cancer | |
| EP3368048A4 (fr) | Méthodes et compositions pour le traitement de l'amyloïdose |